Is primary androgen deprivation therapy a suitable option for Asian patients with prostate cancer compared with radical prostatectomy?

U. Syn Ha, Jin Bong Choi, Jung Im Shim, Minjoo Kang, Eunjung Park, Shinhee Kang, Jooyeon Park, Jangmi Yang, Insun Choi, Jeonghoon Ahn, Cheol Kwak, Chang Wook Jeong, Choung Soo Kim, Seok Soo Byun, Seong Il Seo, Hyun Moo Lee, Seung Ju Lee, Seung Hwan Lee, Byung Ha Chung, Ji Youl Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We conducted a comparative survival analysis between primary androgen deprivation therapy (PADT) and radical prostatectomy (RP) based on nationwide Korean population data that included all patients with prostate cancer. Materials and Methods: This study enrolled 4,538 patients with prostate cancer from the National Health Insurance Service (NHIS) database linked with Korean Central Cancer Registry data who were treated with PADT or RP between January 1, 2007, and December 31, 2014. Kaplan-Meier and multivariate survival analyses stratified by stage (localized and locally advanced) and age (,75 and $75 years) were performed using a Cox proportional hazards model to evaluate treatment effects. Results: Among 18,403 patients from the NHIS database diagnosed with prostate cancer during the study period, 4,538 satisfied inclusion criteria and were included in the analyses. Of these, 3,136 and 1,402 patients underwent RP or received PADT, respectively. Risk of death was significantly increased for patients who received PADT compared with those who underwent RP in the propensity score–matched cohort. In subgroup analyses stratified by stage and age, in every subgroup, patients who received PADT had a significantly increased risk of death compared with those who underwent RP. In particular, a much greater risk was observed for patients with locally advanced prostate cancer. Conclusions: Based on a nationwide survival analysis of nonmetastatic prostate cancer, this study provides valuable clinical implications that favor RP over PDAT for treatment of Asian populations. However, the possibility that survival differences have been overestimated due to not accounting for potential confounding characteristics must be considered.

Original languageEnglish
Pages (from-to)441-449
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number5
DOIs
Publication statusPublished - 2019 Jan 1

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Is primary androgen deprivation therapy a suitable option for Asian patients with prostate cancer compared with radical prostatectomy?'. Together they form a unique fingerprint.

  • Cite this

    Ha, U. S., Choi, J. B., Shim, J. I., Kang, M., Park, E., Kang, S., Park, J., Yang, J., Choi, I., Ahn, J., Kwak, C., Jeong, C. W., Kim, C. S., Byun, S. S., Seo, S. I., Lee, H. M., Lee, S. J., Lee, S. H., Chung, B. H., & Lee, J. Y. (2019). Is primary androgen deprivation therapy a suitable option for Asian patients with prostate cancer compared with radical prostatectomy? JNCCN Journal of the National Comprehensive Cancer Network, 17(5), 441-449. https://doi.org/10.6004/jnccn.2018.7265